This article was originally published in The Gray Sheet
Cancer screening test firm CytoCore receives 510(k) clearance for its SoftPap cervical cell collector Jan. 30 and plans to sign its first U.S. distribution agreements in the coming days for launch by the end of March, the firm said Feb. 5. SoftPap consists of a reusable handle and disposable balloon, which inflates inside the body to collect cervical cells. CytoCore says the system collects better samples than the alternative spatula and brush collection method, and could be used with Cytyc/Hologic's ThinPrep liquid-based Pap test and BD/TriPath's SurePath test. The device will cost $10-$12 out-of-pocket, compared to less than $1 for the reimbursed brush technique, but will "more than prove to be cost-effective," marketing director Dan McMahon claims. SoftPap has been sold in Europe since late December
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.